SecBot SecBot
SECBOTREPLAY Home › Report › CTSO

CTSO · Q3 rev +3%, cash flow breakeven

Cytosorbents Corp · 8-K/A filed Nov 19, 2026 at 07:05 ET

At the news

NEUTRALIMPACT 4/10

8-K/A filed Nov 19, 2026 at 07:05 ET

CytoSorbents filed an 8-K/A amending its Q3 2026 earnings release to correct immaterial errors in foreign currency transaction losses, balance sheet amounts, and certain revenue percentages. The core financial results (revenue, gross profit, operating expenses, operating loss, and cash) are unchanged. The company reported Q3 2026 revenue of $9.7 million (+3% YoY), achieved operating cash flow breakeven of +$43,000 (excluding restructuring payments), and narrowed its adjusted EBITDA loss by 86% to $0.3 million. The company is advancing its DrugSorb-ATR De Novo submission to the FDA for early 2027.

  • Q3 2026 revenue $9.7 million, up 3% from $9.5 million in Q3 2025
  • Gross margin improved to 75% from 70% a year ago
  • Operating loss improved 59% to $1.2 million from $2.9 million in Q3 2025
  • Net loss was $2.1 million ($0.65 per share) vs $3.2 million ($1.01 per share) in Q3 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access